Education
About Us
Working with TipRanks
Follow Us
HLS Therapeutics Inc (TSE:HLS)
TSX:HLS
HLS Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$3.00 - C$5.48
Previous CloseN/A
Volume4.75K
Average Volume (3M)7.01K
Market Cap
C$137.03M
Enterprise ValueC$188.55M
Total Cash (Recent Filing)$17.46M
Total Debt (Recent Filing)$66.45M
Price to Earnings (P/E)―
Beta0.39
Next Earnings
May 08, 2025EPS Estimate
-0.17Last Dividend Ex-Date
Apr 27, 2023Dividend YieldN/A
Share Statistics
EPS (TTM)-0.84
Shares Outstanding31,793,047
10 Day Avg. Volume10,033
30 Day Avg. Volume7,007
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.83
Price to Cash Flow (P/CF)8.10
P/FCF Ratio2.20
Enterprise Value/Market Cap1.38
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.96
Enterprise Value/Ebitda13.34
Forecast
1Y Price Target
C$5.92Price Target Upside33.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
---
HLS Therapeutics Inc News
PremiumCompany Announcements
HLS Therapeutics Appoints Christine Elliott to Board of Directors
PremiumCompany Announcements
HLS Therapeutics to Announce Fiscal 2024 Financial Results
PremiumCompany Announcements
HLS Therapeutics to Announce Q3 2024 Financial Results
PremiumCompany Announcements
HLS Therapeutics to Present at Global Investment Conference
PremiumCompany Announcements
HLS Therapeutics Reports Mixed Q2 Results and Strategic SalesPremiumCompany Announcements
HLS Therapeutics Expands Vascepa Coverage in Canada
PremiumCompany Announcements
HLS Therapeutics Schedules Q2 Financial Results Call---
Bulls Say, Bears Say
Bulls Say
Cash FlowHLS is now in a firmly free cash flow positive position.
Insurance CoverageVascepa has achieved insurance coverage for over 90% and over 95% of Canadians eligible for public and private plans, respectively.
Bears Say
FX HeadwindsThe ongoing trade war's potential impact on the market has led to a decline in the 2025 revenue forecast, primarily due to FX headwinds.
Revenue DeclineRevenue declined 2% to $15.5M, coming in just below the Street's estimate of $15.7M.
Revenue GuidanceThe company has lowered its 2024 revenue guidance.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.51% Insiders
0.01%
Mutual Funds
1.57% Other Institutional Investors
97.89% Public Companies and
Individual Investors
HLS FAQ
What was HLS Therapeutics Inc’s price range in the past 12 months?
HLS Therapeutics Inc lowest stock price was C$3.00 and its highest was C$5.48 in the past 12 months.
What is HLS Therapeutics Inc’s market cap?
HLS Therapeutics Inc’s market cap is C$137.03M.
When is HLS Therapeutics Inc’s upcoming earnings report date?
HLS Therapeutics Inc’s upcoming earnings report date is May 08, 2025 which is in 41 days.
How were HLS Therapeutics Inc’s earnings last quarter?
HLS Therapeutics Inc released its earnings results on Mar 13, 2025. The company reported -C$0.143 earnings per share for the quarter, missing the consensus estimate of -C$0.126 by -C$0.017.
Is HLS Therapeutics Inc overvalued?
According to Wall Street analysts HLS Therapeutics Inc’s price is currently Undervalued.
Does HLS Therapeutics Inc pay dividends?
HLS Therapeutics Inc pays a Quarterly dividend of C$0.05 which represents an annual dividend yield of N/A. See more information on HLS Therapeutics Inc dividends here
What is HLS Therapeutics Inc’s EPS estimate?
HLS Therapeutics Inc’s EPS estimate is -0.17.
How many shares outstanding does HLS Therapeutics Inc have?
HLS Therapeutics Inc has 31,793,047 shares outstanding.
What happened to HLS Therapeutics Inc’s price movement after its last earnings report?
HLS Therapeutics Inc reported an EPS of -C$0.143 in its last earnings report, missing expectations of -C$0.126. Following the earnings report the stock price went down -1.247%.
Which hedge fund is a major shareholder of HLS Therapeutics Inc?
Currently, no hedge funds are holding shares in TSE:HLS
---
HLS Therapeutics Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
C$5.92 (33.94% Upside)
C$5.92 (33.94% Upside)
Insider Transactions
Bought Shares
Worth C$167.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
22.43%
12-Months-Change
Fundamentals
Return on Equity
-23.20%
Trailing 12-Months
Asset Growth
-16.58%
Trailing 12-Months
Company Description
HLS Therapeutics Inc
HLS Therapeutics Inc (HLS) is a specialty pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial-stage promoted, and legacy pharmaceutical products for the North American market. The company operates within the pharmaceutical industry, emphasizing central nervous system, cardiovascular, and other therapeutic areas. HLS leverages its expertise in product management and market access to bring innovative treatments to patients and healthcare providers.
---
HLS Stock 12 Month Forecast
Average Price Target
C$5.92
▲(33.94% Upside)
Technical Analysis
Best Analysts Covering HLS
1 Year
1 Year Success Rate
14/33 ratings generated profit
1 Year Average Return
+9.43%
reiterated a buy rating 14 days ago
Copying David Martin PhD's trades and holding each position for 1 Year would result in 42.42% of your transactions generating a profit, with an average return of +9.43% per trade.
---